The Israeli Fintech Index Q1 2026

The Israeli fintech cohort entered Q1 2026 as one of the most repriced — and most consolidated — segments of the broader Israeli technology universe. Per IVC-LeumiTech, Startup Nation Central, and trade-press coverage in Calcalist, Globes, Bloomberg, and TechCrunch, the quarter marked the first full reading of a public-equity cohort that had been substantially reset between 2022 and 2025, alongside a private-stage layer compressed by acquisition rather than IPO. The composite picture: lower multiples, more strategic exits, fewer mid-cap independents, and a narrower but more profitable public roster.

The public-equity roster

The Israeli-founded fintech public-equity cohort going into Q1 2026 carries seven principal listings on US exchanges: eToro (NASDAQ: ETOR), Pagaya Technologies (NASDAQ: PGY), Payoneer (NASDAQ: PAYO), Riskified (NYSE: RSKD), Lemonade (NYSE: LMND), Hippo Insurance (NYSE: HIPO), and Nayax (TASE: NYAX; NASDAQ: NYAX). All seven are Israeli-founded; six are Israeli-headquartered or maintain primary R&D in Israel.

eToro reopened the cohort in May 2025 at a $4.3 billion Nasdaq IPO valuation, the first major Israeli fintech listing since 2021. Pagaya, by contrast, completed its own institutional inflection: per company disclosures, the AI-driven consumer credit underwriter moved from a $21 million Q1 2024 net loss to an $8 million Q1 2025 net profit, with reported AUM and partner-bank growth supporting a substantially repriced multiple. Payoneer and Riskified entered Q1 2026 trading well below their 2021 IPO peaks but with margins that have stabilized through cost discipline. Lemonade and Hippo, the two insurtech listings, remain the most contested public positions in the cohort, with insurance loss-ratio improvement diverging across the two operators.

The 2025 M&A reset

The defining Q1 2026 read on the broader fintech cohort is structural, not cyclical: the floor in this cycle was reached through acquisition, not endurance.

Two transactions anchor the pattern. Melio, the B2B payments operator, was acquired by New Zealand-listed accounting platform Xero (ASX: XRO) in 2025 at a reported up-to-$3 billion enterprise value, per Globes and Bloomberg coverage. Next Insurance, the small-business insurtech, was acquired by Germany's Munich Re at a reported $2.6 billion valuation. Both transactions resolved post-2021 down-round trajectories through strategic acquisition by mature non-Israeli operators — a pattern materially different from the 2020–2021 Israeli fintech cohort's public-market path.

Per IVC and Calcalist coverage, the M&A multiple for both transactions sat materially below 2021 private-round valuations. The institutional read: the post-2022 fintech reset compressed mid-stage private valuations to levels at which acquisition by mature insurance and accounting operators became the structural exit, replacing public-market endurance as the cohort's primary path.

The mid-market private layer

Below the public roster, the Israeli mid-market fintech layer continued to consolidate around a smaller number of identifiable category leaders: Tipalti (payment automation), Earnix (pricing and rating), Personetics (consumer banking analytics), Capitolis (capital markets infrastructure), Unit (banking-as-a-service), ThetaRay (financial-crime detection), and BioCatch (behavioral biometrics).

Per IVC-LeumiTech Q1 2026 data, this mid-market layer attracted the majority of the quarter's Israeli fintech private-stage capital. The pattern: fewer rounds, larger checks, deeper concentration in operators with demonstrated enterprise customer traction. Seed and pre-seed activity in the fintech category compressed materially against 2021–2022 baselines.

The Q1 2026 funding picture

Specific Q1 2026 financings disclosed in trade-press coverage cluster around two themes. The first — AI-driven underwriting and analytics — anchored by Pagaya's continued partner-bank expansion, Personetics's ongoing institutional deployments, and BioCatch's behavioral-biometrics traction. The second — B2B payments and embedded finance — anchored by Tipalti and Unit, both operating at scale across non-Israeli customer bases.

Notably absent from the Q1 2026 disclosed-financing roster: late-stage consumer-facing Israeli fintech operators of the 2020–2021 era. The retail-trading, neobank, and SMB-payments categories that defined that period are now substantially consolidated, public, or acquired.

The structural read

The Q1 2026 Israeli fintech index reflects a cohort that has resolved most of its post-2022 dislocations. Public-equity multiples have stabilized at lower but sustainable levels. Mid-stage privates have either consolidated through acquisition or compressed to a defensible institutional core. The seed layer has contracted.

The next inflection point: whether the public cohort can produce a second-wave IPO in 2026 beyond eToro — a question dependent on the broader US public-markets reopening for tech and on the post-Wiz, post-CyberArk reference environment for Israeli enterprise software listings.

Source data: IVC-LeumiTech Q1 2026 capital data; Startup Nation Central; SEC filings of cohort issuers; coverage in Calcalist, Globes, Bloomberg, Reuters, TechCrunch, The Information; company-disclosed financial results. Pagaya quarterly figures per company disclosure. Melio/Xero and Next Insurance/Munich Re transaction figures per trade-press coverage. Data current as of Q1 2026.

Related on Olam — Israeli Public Equities & Capital Markets

• The Israeli ADR Universe on NASDAQ and NYSE
• The TASE 35: Sector Weight, Composition, and the Israeli Large-Cap Public-Equity Architecture
• The Dual-Listing Model: NASDAQ-TASE and the PANW Precedent
• The Convertible-Bond Track: Wix, Check Point, and Mature-Stage Capital
• TASE Foreign Institutional Ownership
• ICL Group: The Dead Sea Chemicals Position
• Playtika and the Israeli Public Gaming Position